Systemic lupus erythematosus: new diagnostic and therapeutic approaches
S Lazar, JM Kahlenberg - Annual review of medicine, 2023 - annualreviews.org
Systemic lupus erythematosus (SLE) is a devastating autoimmune disease that can result in
substantial morbidity and mortality. Diagnosis and treatment of SLE are clinical challenges …
substantial morbidity and mortality. Diagnosis and treatment of SLE are clinical challenges …
Emerging concepts of type I interferons in SLE pathogenesis and therapy
Type I interferons have been suspected for decades to have a crucial role in the
pathogenesis of systemic lupus erythematosus (SLE). Evidence has now overturned several …
pathogenesis of systemic lupus erythematosus (SLE). Evidence has now overturned several …
A randomized, placebo‐controlled phase III extension trial of the long‐term safety and tolerability of anifrolumab in active systemic lupus erythematosus
KC Kalunian, R Furie, EF Morand… - Arthritis & …, 2023 - Wiley Online Library
Objective To explore long‐term safety and tolerability of anifrolumab 300 mg compared with
placebo in patients with systemic lupus erythematosus (SLE) who completed a Treatment of …
placebo in patients with systemic lupus erythematosus (SLE) who completed a Treatment of …
Advances in the pathogenesis and treatment of systemic lupus erythematosus
D Accapezzato, R Caccavale, MP Paroli… - International journal of …, 2023 - mdpi.com
Systemic lupus erythematosus (SLE) is a genetically predisposed, female-predominant
disease, characterized by multiple organ damage, that in its most severe forms can be life …
disease, characterized by multiple organ damage, that in its most severe forms can be life …
One year in review 2022: systemic lupus erythematosus
D Zucchi, E Elefante, D Schilirò, V Signorini… - Clinical and …, 2022 - sfera.unife.it
Systemic lupus erythematosus (SLE) is a chronic multisystem auto-immune disease with
extremely varied clinical manifestations and a complex pathogenesis. New insights in SLE …
extremely varied clinical manifestations and a complex pathogenesis. New insights in SLE …
Anifrolumab: first approval
ED Deeks - Drugs, 2021 - Springer
Anifrolumab (anifrolumab-fnia; Saphnelo™) is a monoclonal antibody antagonist of the type
1 interferon receptor (IFNAR). It is being developed by AstraZeneca (under license from …
1 interferon receptor (IFNAR). It is being developed by AstraZeneca (under license from …
Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus
Objectives In patients with systemic lupus erythematosus (SLE), lupus low disease activity
state (LLDAS) attainment is associated with improved outcomes. We investigated LLDAS …
state (LLDAS) attainment is associated with improved outcomes. We investigated LLDAS …
[HTML][HTML] Type I interferons in autoimmunity
R Fernandez-Ruiz, TB Niewold - Journal of Investigative Dermatology, 2022 - Elsevier
Dysregulated IFN-1 responses play crucial roles in the development of multiple forms of
autoimmunity. Many patients with lupus, systemic sclerosis, Sjogren's syndrome, and …
autoimmunity. Many patients with lupus, systemic sclerosis, Sjogren's syndrome, and …
Advances in the management of systemic lupus erythematosus
EF Morand, R Fernandez-Ruiz, A Blazer, TB Niewold - bmj, 2023 - bmj.com
Systemic lupus erythematosus (SLE) is a severe multisystem autoimmune disease that can
cause injury in almost every body system. While considered a classic example of …
cause injury in almost every body system. While considered a classic example of …
Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider
Objectives To systematically review the literature for assay methods that aim to evaluate type
I interferon (IFN-I) pathway activation and to harmonise-related terminology. Methods Three …
I interferon (IFN-I) pathway activation and to harmonise-related terminology. Methods Three …